Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Economic Competition | 11 | 2022 | 219 | 3.870 |
Why?
|
Mental Health Services | 37 | 2024 | 1716 | 3.620 |
Why?
|
Drug Industry | 20 | 2024 | 788 | 3.210 |
Why?
|
Drug Costs | 20 | 2024 | 1183 | 2.810 |
Why?
|
Medicaid | 27 | 2024 | 2813 | 2.590 |
Why?
|
Drugs, Generic | 10 | 2021 | 448 | 2.580 |
Why?
|
Mental Disorders | 36 | 2024 | 6823 | 2.560 |
Why?
|
Managed Care Programs | 21 | 2021 | 937 | 2.420 |
Why?
|
Patient Protection and Affordable Care Act | 12 | 2021 | 1186 | 2.150 |
Why?
|
Health Policy | 21 | 2024 | 2679 | 1.860 |
Why?
|
Government Regulation | 9 | 2020 | 523 | 1.750 |
Why?
|
Substance-Related Disorders | 19 | 2024 | 4413 | 1.710 |
Why?
|
Insurance, Psychiatric | 9 | 2014 | 66 | 1.690 |
Why?
|
Insurance Coverage | 19 | 2021 | 1935 | 1.670 |
Why?
|
Behavior, Addictive | 5 | 2022 | 462 | 1.670 |
Why?
|
Medicare Part D | 6 | 2019 | 354 | 1.550 |
Why?
|
Narcotic Antagonists | 4 | 2020 | 585 | 1.510 |
Why?
|
Mental Health | 11 | 2023 | 3251 | 1.510 |
Why?
|
Medicare | 19 | 2023 | 6773 | 1.480 |
Why?
|
Health Services Accessibility | 18 | 2021 | 5425 | 1.450 |
Why?
|
Insurance, Health | 15 | 2022 | 2493 | 1.400 |
Why?
|
United States | 113 | 2024 | 72339 | 1.350 |
Why?
|
Drug Approval | 7 | 2022 | 812 | 1.290 |
Why?
|
Prescription Drugs | 5 | 2024 | 631 | 1.280 |
Why?
|
Buprenorphine | 3 | 2020 | 656 | 1.180 |
Why?
|
Physician Assistants | 2 | 2020 | 190 | 1.150 |
Why?
|
Medicare Part C | 3 | 2019 | 330 | 1.140 |
Why?
|
Cost Savings | 6 | 2018 | 911 | 1.130 |
Why?
|
Nurse Practitioners | 2 | 2020 | 269 | 1.090 |
Why?
|
Health Care Reform | 10 | 2019 | 1247 | 1.050 |
Why?
|
Drug and Narcotic Control | 3 | 2017 | 144 | 0.990 |
Why?
|
Health Benefit Plans, Employee | 10 | 2014 | 332 | 0.980 |
Why?
|
Insurance, Pharmaceutical Services | 8 | 2021 | 348 | 0.980 |
Why?
|
Financing, Government | 6 | 2021 | 472 | 0.950 |
Why?
|
Eligibility Determination | 6 | 2019 | 420 | 0.930 |
Why?
|
Budgets | 2 | 2019 | 230 | 0.930 |
Why?
|
Health Care Sector | 4 | 2019 | 195 | 0.900 |
Why?
|
Drug Prescriptions | 7 | 2019 | 1668 | 0.880 |
Why?
|
Cost Sharing | 10 | 2021 | 409 | 0.880 |
Why?
|
Schizophrenia | 11 | 2020 | 6930 | 0.880 |
Why?
|
United States Food and Drug Administration | 13 | 2024 | 1662 | 0.850 |
Why?
|
Public Health | 5 | 2021 | 2672 | 0.840 |
Why?
|
Opioid-Related Disorders | 6 | 2021 | 2164 | 0.840 |
Why?
|
Quality of Health Care | 16 | 2016 | 4320 | 0.840 |
Why?
|
Contracts | 3 | 2021 | 60 | 0.830 |
Why?
|
Public Policy | 4 | 2022 | 557 | 0.820 |
Why?
|
Insurance Benefits | 4 | 2019 | 186 | 0.800 |
Why?
|
Delivery of Health Care | 12 | 2023 | 5333 | 0.780 |
Why?
|
Legislation, Drug | 3 | 2019 | 214 | 0.770 |
Why?
|
Policy | 3 | 2023 | 506 | 0.770 |
Why?
|
Costs and Cost Analysis | 7 | 2022 | 1664 | 0.750 |
Why?
|
Bankruptcy | 1 | 2021 | 26 | 0.730 |
Why?
|
Social Responsibility | 2 | 2022 | 385 | 0.710 |
Why?
|
Prescription Fees | 4 | 2005 | 153 | 0.700 |
Why?
|
Choice Behavior | 3 | 2013 | 825 | 0.690 |
Why?
|
Employment | 6 | 2020 | 1114 | 0.690 |
Why?
|
Orphan Drug Production | 1 | 2020 | 48 | 0.660 |
Why?
|
Social Security | 4 | 2013 | 101 | 0.650 |
Why?
|
Naloxone | 2 | 2019 | 370 | 0.650 |
Why?
|
Cost Control | 5 | 2019 | 627 | 0.650 |
Why?
|
Analgesics, Opioid | 4 | 2020 | 3805 | 0.640 |
Why?
|
Mentally Ill Persons | 2 | 2018 | 125 | 0.620 |
Why?
|
Opiate Substitution Treatment | 2 | 2019 | 444 | 0.620 |
Why?
|
Friction | 1 | 2018 | 59 | 0.620 |
Why?
|
Health Expenditures | 13 | 2022 | 2362 | 0.600 |
Why?
|
Pharmacies | 1 | 2020 | 168 | 0.600 |
Why?
|
Reimbursement, Incentive | 7 | 2021 | 542 | 0.600 |
Why?
|
Nursing Homes | 2 | 2016 | 1083 | 0.590 |
Why?
|
Primary Health Care | 12 | 2021 | 4678 | 0.580 |
Why?
|
Insurance Carriers | 2 | 2017 | 155 | 0.570 |
Why?
|
Social Control, Formal | 1 | 2017 | 107 | 0.560 |
Why?
|
Humans | 160 | 2024 | 761208 | 0.560 |
Why?
|
Reimbursement Mechanisms | 3 | 2021 | 667 | 0.540 |
Why?
|
United States Dept. of Health and Human Services | 1 | 2016 | 88 | 0.540 |
Why?
|
Formularies as Topic | 3 | 2007 | 94 | 0.520 |
Why?
|
Rural Health Services | 1 | 2019 | 384 | 0.520 |
Why?
|
Insurance, Disability | 2 | 2013 | 26 | 0.500 |
Why?
|
Federal Government | 7 | 2021 | 266 | 0.470 |
Why?
|
Crisis Intervention | 2 | 2024 | 109 | 0.470 |
Why?
|
Antipsychotic Agents | 10 | 2021 | 3064 | 0.460 |
Why?
|
Cooperative Behavior | 2 | 2011 | 1506 | 0.460 |
Why?
|
Depression | 8 | 2023 | 8132 | 0.450 |
Why?
|
Fentanyl | 1 | 2017 | 433 | 0.440 |
Why?
|
Depressive Disorder | 6 | 2008 | 3727 | 0.430 |
Why?
|
Healthcare Disparities | 8 | 2011 | 3354 | 0.430 |
Why?
|
Employment, Supported | 1 | 2013 | 21 | 0.430 |
Why?
|
Pharmaceutical Preparations | 4 | 2024 | 1086 | 0.420 |
Why?
|
Insurance Selection Bias | 3 | 2006 | 69 | 0.400 |
Why?
|
State Government | 2 | 2013 | 384 | 0.380 |
Why?
|
Psychotropic Drugs | 6 | 2021 | 885 | 0.380 |
Why?
|
Vulnerable Populations | 1 | 2016 | 706 | 0.370 |
Why?
|
Chemistry, Pharmaceutical | 3 | 2008 | 274 | 0.370 |
Why?
|
Health Care Costs | 5 | 2014 | 3239 | 0.360 |
Why?
|
Models, Economic | 1 | 2014 | 714 | 0.350 |
Why?
|
Evidence-Based Medicine | 6 | 2016 | 3691 | 0.350 |
Why?
|
Commerce | 3 | 2024 | 608 | 0.350 |
Why?
|
Anti-Anxiety Agents | 2 | 2010 | 397 | 0.350 |
Why?
|
Health Services | 1 | 2015 | 750 | 0.350 |
Why?
|
Florida | 5 | 2013 | 429 | 0.350 |
Why?
|
Bipolar Disorder | 7 | 2013 | 5092 | 0.340 |
Why?
|
Residential Treatment | 2 | 2021 | 111 | 0.330 |
Why?
|
Preventive Health Services | 1 | 2014 | 567 | 0.330 |
Why?
|
Cyclohexanecarboxylic Acids | 1 | 2010 | 140 | 0.320 |
Why?
|
Quality Assurance, Health Care | 7 | 2010 | 2164 | 0.320 |
Why?
|
Private Sector | 5 | 2021 | 394 | 0.320 |
Why?
|
Income | 7 | 2023 | 1869 | 0.320 |
Why?
|
Antineoplastic Agents | 2 | 2022 | 13632 | 0.320 |
Why?
|
Depressive Disorder, Major | 5 | 2013 | 4767 | 0.320 |
Why?
|
Forecasting | 7 | 2019 | 2928 | 0.320 |
Why?
|
Amines | 1 | 2010 | 280 | 0.310 |
Why?
|
Off-Label Use | 1 | 2010 | 185 | 0.300 |
Why?
|
Risk Adjustment | 3 | 2019 | 601 | 0.300 |
Why?
|
Antidepressive Agents | 6 | 2010 | 2893 | 0.290 |
Why?
|
Violence | 1 | 2013 | 935 | 0.280 |
Why?
|
Capitation Fee | 4 | 2007 | 115 | 0.280 |
Why?
|
Ethylene Glycols | 1 | 2018 | 196 | 0.270 |
Why?
|
Drug Utilization | 4 | 2012 | 1188 | 0.270 |
Why?
|
Emergency Medical Services | 1 | 2018 | 1920 | 0.270 |
Why?
|
Behavioral Medicine | 1 | 2007 | 49 | 0.270 |
Why?
|
Freedom | 1 | 2006 | 69 | 0.270 |
Why?
|
Cost of Illness | 3 | 2013 | 1936 | 0.270 |
Why?
|
Negotiating | 1 | 2008 | 151 | 0.270 |
Why?
|
Community Health Services | 1 | 2011 | 654 | 0.270 |
Why?
|
Community Mental Health Services | 2 | 2006 | 387 | 0.260 |
Why?
|
September 11 Terrorist Attacks | 1 | 2006 | 105 | 0.250 |
Why?
|
Fluorine Radioisotopes | 1 | 2018 | 420 | 0.240 |
Why?
|
Patients | 1 | 2011 | 906 | 0.240 |
Why?
|
Cost-Benefit Analysis | 10 | 2010 | 5493 | 0.240 |
Why?
|
Health Care Rationing | 4 | 2021 | 435 | 0.240 |
Why?
|
Grief | 1 | 2006 | 254 | 0.230 |
Why?
|
Neoplasms | 3 | 2022 | 22140 | 0.220 |
Why?
|
Economics, Pharmaceutical | 1 | 2024 | 87 | 0.220 |
Why?
|
Mass Media | 1 | 2006 | 303 | 0.220 |
Why?
|
gamma-Aminobutyric Acid | 1 | 2010 | 1139 | 0.220 |
Why?
|
Population Density | 1 | 2024 | 193 | 0.220 |
Why?
|
Capital Expenditures | 1 | 2003 | 27 | 0.220 |
Why?
|
Workplace | 2 | 2020 | 864 | 0.210 |
Why?
|
Clinical Trials as Topic | 6 | 2022 | 8003 | 0.210 |
Why?
|
Aniline Compounds | 1 | 2018 | 1073 | 0.200 |
Why?
|
Aged | 26 | 2023 | 169288 | 0.200 |
Why?
|
Physician Incentive Plans | 5 | 2006 | 164 | 0.190 |
Why?
|
Patient Care Management | 2 | 2017 | 303 | 0.190 |
Why?
|
Drug Evaluation | 1 | 2003 | 641 | 0.190 |
Why?
|
Antidepressive Agents, Second-Generation | 1 | 2004 | 489 | 0.190 |
Why?
|
Research Support as Topic | 2 | 2021 | 697 | 0.190 |
Why?
|
Patient Readmission | 1 | 2015 | 3265 | 0.190 |
Why?
|
Patents as Topic | 3 | 2024 | 111 | 0.190 |
Why?
|
Adult | 41 | 2023 | 221119 | 0.180 |
Why?
|
Marketing of Health Services | 4 | 2011 | 150 | 0.180 |
Why?
|
Government Agencies | 1 | 2021 | 160 | 0.180 |
Why?
|
Standard of Care | 2 | 2021 | 550 | 0.180 |
Why?
|
Public Sector | 2 | 2021 | 264 | 0.180 |
Why?
|
State Health Plans | 1 | 2003 | 219 | 0.180 |
Why?
|
Income Tax | 1 | 2021 | 24 | 0.180 |
Why?
|
Health Promotion | 2 | 2018 | 2205 | 0.180 |
Why?
|
Medicare Part B | 1 | 2021 | 117 | 0.180 |
Why?
|
Public Health Administration | 1 | 2003 | 242 | 0.170 |
Why?
|
Politics | 3 | 2012 | 814 | 0.170 |
Why?
|
Health Care Surveys | 8 | 2020 | 2425 | 0.170 |
Why?
|
Certification | 1 | 2023 | 418 | 0.170 |
Why?
|
Community Health Centers | 1 | 2023 | 461 | 0.170 |
Why?
|
Poverty | 4 | 2023 | 2691 | 0.170 |
Why?
|
Physicians | 3 | 2019 | 4584 | 0.170 |
Why?
|
Psychotic Disorders | 1 | 2014 | 3220 | 0.160 |
Why?
|
Financial Management | 1 | 2021 | 160 | 0.160 |
Why?
|
Guideline Adherence | 2 | 2011 | 2220 | 0.160 |
Why?
|
National Health Insurance, United States | 2 | 2011 | 100 | 0.160 |
Why?
|
Quality of Life | 3 | 2022 | 13367 | 0.160 |
Why?
|
Male | 43 | 2020 | 360693 | 0.150 |
Why?
|
Biological Products | 1 | 2007 | 915 | 0.150 |
Why?
|
Names | 1 | 2018 | 54 | 0.150 |
Why?
|
Long-Term Care | 2 | 2015 | 630 | 0.150 |
Why?
|
Neonatal Abstinence Syndrome | 1 | 2019 | 109 | 0.150 |
Why?
|
Suicide | 3 | 2023 | 1602 | 0.150 |
Why?
|
Middle Aged | 37 | 2023 | 220853 | 0.150 |
Why?
|
Patient Compliance | 2 | 2005 | 2688 | 0.150 |
Why?
|
Drug Labeling | 2 | 2010 | 248 | 0.150 |
Why?
|
Cicatrix | 1 | 2023 | 793 | 0.140 |
Why?
|
Adolescent | 25 | 2020 | 88298 | 0.140 |
Why?
|
Female | 45 | 2020 | 392544 | 0.140 |
Why?
|
Privatization | 2 | 2009 | 41 | 0.140 |
Why?
|
Health Services Research | 6 | 2011 | 1807 | 0.140 |
Why?
|
Critical Care | 1 | 2009 | 2696 | 0.140 |
Why?
|
Positron-Emission Tomography | 3 | 2018 | 6585 | 0.130 |
Why?
|
Medical Assistance | 1 | 2016 | 108 | 0.130 |
Why?
|
Reward | 1 | 2022 | 968 | 0.120 |
Why?
|
Child Welfare | 1 | 2019 | 521 | 0.120 |
Why?
|
Psychotherapy | 6 | 2008 | 1646 | 0.120 |
Why?
|
Behavior Therapy | 1 | 2020 | 875 | 0.120 |
Why?
|
Amyloid beta-Peptides | 1 | 2018 | 3840 | 0.120 |
Why?
|
Psychiatry | 3 | 2021 | 1699 | 0.120 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 2 | 2012 | 3707 | 0.120 |
Why?
|
Diagnostic Tests, Routine | 1 | 2020 | 788 | 0.110 |
Why?
|
Diagnosis, Dual (Psychiatry) | 1 | 2014 | 303 | 0.110 |
Why?
|
Needs Assessment | 2 | 2018 | 1141 | 0.110 |
Why?
|
Substance Withdrawal Syndrome | 1 | 2018 | 624 | 0.110 |
Why?
|
Drug Utilization Review | 2 | 2005 | 248 | 0.110 |
Why?
|
Health Services Needs and Demand | 2 | 2013 | 1401 | 0.110 |
Why?
|
Regional Health Planning | 1 | 2013 | 96 | 0.100 |
Why?
|
Young Adult | 10 | 2020 | 59221 | 0.100 |
Why?
|
Disease Transmission, Infectious | 1 | 2018 | 561 | 0.100 |
Why?
|
Cardiac Surgical Procedures | 1 | 2018 | 3627 | 0.100 |
Why?
|
Germany | 1 | 2015 | 872 | 0.100 |
Why?
|
History, 21st Century | 2 | 2016 | 1567 | 0.100 |
Why?
|
Regression Analysis | 5 | 2011 | 6345 | 0.100 |
Why?
|
Case Management | 1 | 2014 | 272 | 0.100 |
Why?
|
Conduct Disorder | 1 | 2013 | 245 | 0.100 |
Why?
|
Occupational Health | 1 | 2018 | 807 | 0.090 |
Why?
|
Financing, Personal | 3 | 2011 | 308 | 0.090 |
Why?
|
Models, Theoretical | 2 | 2021 | 3571 | 0.090 |
Why?
|
Phosphoric Diester Hydrolases | 1 | 2012 | 201 | 0.090 |
Why?
|
Diffusion of Innovation | 2 | 2008 | 730 | 0.090 |
Why?
|
Quinazolinones | 1 | 2012 | 221 | 0.090 |
Why?
|
Logistic Models | 7 | 2011 | 13249 | 0.090 |
Why?
|
Insurance Claim Review | 3 | 2010 | 741 | 0.090 |
Why?
|
Netherlands | 1 | 2015 | 2222 | 0.090 |
Why?
|
Aged, 80 and over | 9 | 2015 | 58952 | 0.090 |
Why?
|
Disease Management | 2 | 2011 | 2507 | 0.090 |
Why?
|
Program Development | 2 | 2018 | 1294 | 0.090 |
Why?
|
Comorbidity | 4 | 2014 | 10516 | 0.080 |
Why?
|
Hospitals, Private | 1 | 2009 | 63 | 0.080 |
Why?
|
Databases, Factual | 3 | 2019 | 7966 | 0.080 |
Why?
|
Ambulatory Care | 5 | 2009 | 2770 | 0.080 |
Why?
|
Insurance, Long-Term Care | 1 | 2009 | 18 | 0.080 |
Why?
|
Rural Population | 1 | 2019 | 2277 | 0.080 |
Why?
|
Rehabilitation, Vocational | 1 | 2009 | 74 | 0.080 |
Why?
|
Treatment Outcome | 10 | 2021 | 64681 | 0.080 |
Why?
|
Hydroxamic Acids | 1 | 2011 | 479 | 0.080 |
Why?
|
History, 20th Century | 3 | 2009 | 2765 | 0.080 |
Why?
|
Delivery of Health Care, Integrated | 2 | 2014 | 940 | 0.080 |
Why?
|
Stress Disorders, Post-Traumatic | 1 | 2006 | 4575 | 0.080 |
Why?
|
Home Care Services | 1 | 2015 | 647 | 0.080 |
Why?
|
Observation | 1 | 2010 | 310 | 0.080 |
Why?
|
Group Purchasing | 1 | 2007 | 9 | 0.080 |
Why?
|
Referral and Consultation | 1 | 2021 | 3608 | 0.080 |
Why?
|
Hospitals, Psychiatric | 1 | 2009 | 318 | 0.080 |
Why?
|
Alphapapillomavirus | 1 | 2011 | 218 | 0.070 |
Why?
|
Antimanic Agents | 2 | 2009 | 520 | 0.070 |
Why?
|
Salaries and Fringe Benefits | 3 | 2023 | 256 | 0.070 |
Why?
|
Comprehension | 1 | 2013 | 619 | 0.070 |
Why?
|
Program Evaluation | 2 | 2006 | 2489 | 0.070 |
Why?
|
Socioeconomic Factors | 5 | 2013 | 7804 | 0.070 |
Why?
|
Social Stigma | 1 | 2013 | 770 | 0.070 |
Why?
|
Prisons | 1 | 2009 | 174 | 0.070 |
Why?
|
Licensure | 1 | 2007 | 126 | 0.070 |
Why?
|
Food | 1 | 2011 | 768 | 0.070 |
Why?
|
Social Work, Psychiatric | 1 | 2006 | 21 | 0.070 |
Why?
|
Government Programs | 1 | 2009 | 278 | 0.070 |
Why?
|
Employer Health Costs | 1 | 2006 | 21 | 0.070 |
Why?
|
Taxes | 1 | 2009 | 221 | 0.070 |
Why?
|
Histone Deacetylase Inhibitors | 1 | 2011 | 774 | 0.070 |
Why?
|
Hotlines | 1 | 2006 | 55 | 0.070 |
Why?
|
Parents | 1 | 2020 | 3564 | 0.060 |
Why?
|
Congresses as Topic | 1 | 2011 | 803 | 0.060 |
Why?
|
Quinazolines | 1 | 2012 | 1371 | 0.060 |
Why?
|
Qualitative Research | 1 | 2016 | 3024 | 0.060 |
Why?
|
Probability | 2 | 2009 | 2478 | 0.060 |
Why?
|
Child | 8 | 2020 | 80152 | 0.060 |
Why?
|
National Health Programs | 1 | 2009 | 440 | 0.060 |
Why?
|
Marketing | 1 | 2007 | 220 | 0.060 |
Why?
|
Reference Standards | 1 | 2009 | 1005 | 0.060 |
Why?
|
Safety | 1 | 2010 | 1151 | 0.060 |
Why?
|
Pharmaceutical Services | 1 | 2006 | 141 | 0.060 |
Why?
|
Cardiotonic Agents | 1 | 2007 | 540 | 0.060 |
Why?
|
Disclosure | 1 | 2010 | 747 | 0.060 |
Why?
|
Alzheimer Disease | 3 | 2011 | 8603 | 0.060 |
Why?
|
Diagnostic and Statistical Manual of Mental Disorders | 2 | 2008 | 1990 | 0.060 |
Why?
|
Combined Modality Therapy | 2 | 2014 | 8519 | 0.060 |
Why?
|
New York City | 1 | 2006 | 730 | 0.060 |
Why?
|
New York | 1 | 2006 | 875 | 0.060 |
Why?
|
DNA, Viral | 1 | 2011 | 2195 | 0.060 |
Why?
|
Health Maintenance Organizations | 1 | 2006 | 658 | 0.060 |
Why?
|
Advisory Committees | 1 | 2008 | 788 | 0.060 |
Why?
|
Models, Econometric | 2 | 2002 | 215 | 0.060 |
Why?
|
Organizational Innovation | 1 | 2007 | 538 | 0.050 |
Why?
|
Practice Management, Medical | 1 | 2005 | 191 | 0.050 |
Why?
|
Data Collection | 4 | 2007 | 3320 | 0.050 |
Why?
|
Hospitalization | 4 | 2021 | 10707 | 0.050 |
Why?
|
Emigrants and Immigrants | 1 | 2010 | 544 | 0.050 |
Why?
|
Cost Allocation | 1 | 2003 | 48 | 0.050 |
Why?
|
Quality-Adjusted Life Years | 1 | 2010 | 1723 | 0.050 |
Why?
|
Psychiatric Department, Hospital | 1 | 2003 | 125 | 0.050 |
Why?
|
Patient Dropouts | 1 | 2005 | 411 | 0.050 |
Why?
|
Quality Indicators, Health Care | 3 | 2008 | 1789 | 0.050 |
Why?
|
Provider-Sponsored Organizations | 1 | 2002 | 12 | 0.050 |
Why?
|
Insurance, Health, Reimbursement | 1 | 2006 | 385 | 0.050 |
Why?
|
Maryland | 1 | 2003 | 277 | 0.050 |
Why?
|
Drug Discovery | 1 | 2010 | 1050 | 0.050 |
Why?
|
Insurance Claim Reporting | 3 | 2011 | 165 | 0.050 |
Why?
|
Brain | 2 | 2018 | 27092 | 0.050 |
Why?
|
Oregon | 3 | 2007 | 147 | 0.050 |
Why?
|
Interinstitutional Relations | 1 | 2003 | 236 | 0.050 |
Why?
|
Radiopharmaceuticals | 1 | 2011 | 2683 | 0.050 |
Why?
|
Continuity of Patient Care | 1 | 2009 | 1069 | 0.050 |
Why?
|
Information Dissemination | 1 | 2010 | 1129 | 0.050 |
Why?
|
Social Justice | 1 | 2006 | 477 | 0.050 |
Why?
|
Child Health Services | 1 | 2007 | 644 | 0.050 |
Why?
|
Antibodies, Monoclonal | 1 | 2018 | 9187 | 0.050 |
Why?
|
Medically Uninsured | 2 | 2006 | 834 | 0.050 |
Why?
|
Health Facilities, Proprietary | 1 | 2021 | 37 | 0.050 |
Why?
|
China | 2 | 2022 | 2374 | 0.050 |
Why?
|
Occupations | 1 | 2023 | 517 | 0.050 |
Why?
|
Drugs, Investigational | 1 | 2003 | 212 | 0.050 |
Why?
|
Methylphenidate | 1 | 2005 | 488 | 0.050 |
Why?
|
Insurance | 1 | 2002 | 113 | 0.040 |
Why?
|
Organizations, Nonprofit | 1 | 2021 | 105 | 0.040 |
Why?
|
Patient-Centered Care | 1 | 2010 | 1427 | 0.040 |
Why?
|
Cohort Studies | 7 | 2013 | 41496 | 0.040 |
Why?
|
Patient Acceptance of Health Care | 1 | 2013 | 3200 | 0.040 |
Why?
|
Administrative Personnel | 1 | 2021 | 183 | 0.040 |
Why?
|
Emergency Service, Hospital | 1 | 2019 | 7865 | 0.040 |
Why?
|
Efficiency | 2 | 2018 | 476 | 0.040 |
Why?
|
Organizational Objectives | 1 | 2000 | 426 | 0.040 |
Why?
|
Proton Pump Inhibitors | 1 | 2003 | 534 | 0.040 |
Why?
|
Practice Guidelines as Topic | 3 | 2011 | 7400 | 0.040 |
Why?
|
Inpatients | 1 | 2009 | 2545 | 0.040 |
Why?
|
Registries | 2 | 2011 | 8247 | 0.040 |
Why?
|
National Institutes of Health (U.S.) | 1 | 2021 | 793 | 0.040 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2003 | 1331 | 0.040 |
Why?
|
Europe | 1 | 2004 | 3423 | 0.040 |
Why?
|
Organizational Case Studies | 1 | 2018 | 301 | 0.040 |
Why?
|
Severity of Illness Index | 3 | 2010 | 15841 | 0.040 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 2003 | 1504 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2009 | 10756 | 0.030 |
Why?
|
Genetic Variation | 1 | 2012 | 6567 | 0.030 |
Why?
|
Central Nervous System Stimulants | 1 | 2005 | 1176 | 0.030 |
Why?
|
Decision Making | 2 | 2016 | 3931 | 0.030 |
Why?
|
Health Personnel | 1 | 2010 | 3337 | 0.030 |
Why?
|
Economics, Hospital | 2 | 2009 | 210 | 0.030 |
Why?
|
Protein Kinase Inhibitors | 1 | 2012 | 5662 | 0.030 |
Why?
|
Cognition | 1 | 2013 | 6988 | 0.030 |
Why?
|
Biomedical Research | 2 | 2016 | 3434 | 0.030 |
Why?
|
Multivariate Analysis | 2 | 2009 | 12052 | 0.030 |
Why?
|
Sex Factors | 4 | 2011 | 10553 | 0.030 |
Why?
|
Risk Factors | 4 | 2018 | 74239 | 0.030 |
Why?
|
Organizational Culture | 1 | 2018 | 509 | 0.030 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 1 | 2012 | 5321 | 0.030 |
Why?
|
Emergency Services, Psychiatric | 1 | 2013 | 63 | 0.030 |
Why?
|
Coronary Disease | 1 | 2007 | 5921 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2009 | 26071 | 0.030 |
Why?
|
Group Practice | 2 | 2005 | 151 | 0.030 |
Why?
|
Gross Domestic Product | 1 | 2012 | 77 | 0.020 |
Why?
|
Food-Drug Interactions | 1 | 2011 | 24 | 0.020 |
Why?
|
Drug Therapy, Combination | 2 | 2012 | 6304 | 0.020 |
Why?
|
Metabolic Clearance Rate | 1 | 2011 | 362 | 0.020 |
Why?
|
Pandemics | 2 | 2021 | 8663 | 0.020 |
Why?
|
Consensus | 1 | 2021 | 3134 | 0.020 |
Why?
|
Biological Availability | 1 | 2011 | 389 | 0.020 |
Why?
|
Health Priorities | 1 | 2013 | 375 | 0.020 |
Why?
|
Patient Satisfaction | 1 | 2003 | 3453 | 0.020 |
Why?
|
California | 2 | 2005 | 1431 | 0.020 |
Why?
|
Health Surveys | 2 | 2010 | 4037 | 0.020 |
Why?
|
Legislation as Topic | 1 | 2009 | 76 | 0.020 |
Why?
|
Japan | 1 | 2013 | 1378 | 0.020 |
Why?
|
Health Services Misuse | 1 | 2011 | 244 | 0.020 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2003 | 3245 | 0.020 |
Why?
|
Hospital Bed Capacity | 1 | 2009 | 206 | 0.020 |
Why?
|
Nausea | 1 | 2011 | 678 | 0.020 |
Why?
|
Vomiting | 1 | 2011 | 650 | 0.020 |
Why?
|
Models, Statistical | 1 | 2003 | 5081 | 0.020 |
Why?
|
Vaginal Smears | 1 | 2011 | 499 | 0.020 |
Why?
|
Review Literature as Topic | 1 | 2010 | 348 | 0.020 |
Why?
|
Chronic Disease | 1 | 2003 | 9319 | 0.020 |
Why?
|
Lung Neoplasms | 1 | 2012 | 13385 | 0.020 |
Why?
|
Confidence Intervals | 1 | 2013 | 2928 | 0.020 |
Why?
|
Endpoint Determination | 1 | 2010 | 590 | 0.020 |
Why?
|
Area Under Curve | 1 | 2011 | 1636 | 0.020 |
Why?
|
Physician Executives | 1 | 2008 | 134 | 0.020 |
Why?
|
Unemployment | 1 | 2009 | 210 | 0.020 |
Why?
|
Decision Making, Organizational | 1 | 2007 | 136 | 0.020 |
Why?
|
ras Proteins | 1 | 2012 | 1055 | 0.020 |
Why?
|
Academies and Institutes | 1 | 2009 | 318 | 0.020 |
Why?
|
Molecular Biology | 1 | 2010 | 573 | 0.020 |
Why?
|
Postal Service | 1 | 2006 | 96 | 0.020 |
Why?
|
Morals | 1 | 2009 | 289 | 0.020 |
Why?
|
Child, Preschool | 3 | 2019 | 42224 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2003 | 10218 | 0.020 |
Why?
|
Postoperative Complications | 1 | 2018 | 15637 | 0.020 |
Why?
|
Cross-Over Studies | 1 | 2011 | 2082 | 0.020 |
Why?
|
Fasting | 1 | 2011 | 1603 | 0.020 |
Why?
|
Retrospective Studies | 4 | 2007 | 80674 | 0.020 |
Why?
|
Chile | 1 | 2005 | 256 | 0.020 |
Why?
|
Washington | 1 | 2005 | 314 | 0.020 |
Why?
|
Eating | 1 | 2011 | 1535 | 0.010 |
Why?
|
Minnesota | 1 | 2005 | 337 | 0.010 |
Why?
|
Puerto Rico | 1 | 2005 | 378 | 0.010 |
Why?
|
Fatigue | 1 | 2011 | 1550 | 0.010 |
Why?
|
Proto-Oncogene Proteins p21(ras) | 1 | 2012 | 1746 | 0.010 |
Why?
|
Sex Distribution | 1 | 2009 | 2277 | 0.010 |
Why?
|
Psychiatric Status Rating Scales | 2 | 2005 | 6011 | 0.010 |
Why?
|
Health Status Indicators | 1 | 2009 | 970 | 0.010 |
Why?
|
Visual Cortex | 1 | 2012 | 1104 | 0.010 |
Why?
|
Drug Design | 1 | 2009 | 1045 | 0.010 |
Why?
|
Administration, Oral | 1 | 2011 | 4015 | 0.010 |
Why?
|
Boston | 2 | 2007 | 9327 | 0.010 |
Why?
|
Drug Administration Schedule | 1 | 2011 | 4851 | 0.010 |
Why?
|
Prospective Studies | 1 | 2018 | 54435 | 0.010 |
Why?
|
Indoles | 1 | 2011 | 1830 | 0.010 |
Why?
|
Infant, Newborn | 2 | 2019 | 26199 | 0.010 |
Why?
|
Risk Reduction Behavior | 1 | 2010 | 1111 | 0.010 |
Why?
|
Interdisciplinary Communication | 1 | 2009 | 931 | 0.010 |
Why?
|
Fluorodeoxyglucose F18 | 1 | 2011 | 2024 | 0.010 |
Why?
|
Independent Practice Associations | 1 | 2002 | 21 | 0.010 |
Why?
|
Family Therapy | 1 | 2004 | 214 | 0.010 |
Why?
|
Mass Screening | 2 | 2011 | 5426 | 0.010 |
Why?
|
Contract Services | 1 | 2002 | 89 | 0.010 |
Why?
|
Inflation, Economic | 1 | 2002 | 30 | 0.010 |
Why?
|
Models, Genetic | 1 | 2012 | 3430 | 0.010 |
Why?
|
Disease-Free Survival | 1 | 2012 | 6819 | 0.010 |
Why?
|
Disability Evaluation | 1 | 2009 | 1834 | 0.010 |
Why?
|
Medical Records Systems, Computerized | 1 | 2007 | 1191 | 0.010 |
Why?
|
Medication Adherence | 1 | 2013 | 2175 | 0.010 |
Why?
|
Episode of Care | 1 | 2002 | 128 | 0.010 |
Why?
|
Suicide, Attempted | 1 | 2010 | 1402 | 0.010 |
Why?
|
Infant | 2 | 2019 | 36169 | 0.010 |
Why?
|
Breast Neoplasms | 1 | 2008 | 20982 | 0.010 |
Why?
|
Saccharomyces cerevisiae | 1 | 2012 | 2667 | 0.010 |
Why?
|
Social Class | 1 | 2010 | 1993 | 0.010 |
Why?
|
Antidepressive Agents, Tricyclic | 1 | 2003 | 431 | 0.010 |
Why?
|
Decision Support Techniques | 1 | 2011 | 2004 | 0.010 |
Why?
|
Age Factors | 2 | 2011 | 18384 | 0.010 |
Why?
|
Expert Testimony | 1 | 2003 | 365 | 0.010 |
Why?
|
Psychotherapy, Group | 1 | 2004 | 413 | 0.010 |
Why?
|
Lithium | 1 | 2003 | 596 | 0.010 |
Why?
|
Proto-Oncogene Proteins | 1 | 2012 | 4513 | 0.010 |
Why?
|
Motivation | 1 | 2009 | 2002 | 0.010 |
Why?
|
Benchmarking | 1 | 2005 | 1045 | 0.010 |
Why?
|
Papillomavirus Infections | 1 | 2011 | 1616 | 0.010 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2011 | 2019 | 0.010 |
Why?
|
Delphi Technique | 1 | 2002 | 848 | 0.010 |
Why?
|
Research Personnel | 1 | 2003 | 588 | 0.010 |
Why?
|
Meta-Analysis as Topic | 1 | 2003 | 1381 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 2012 | 3534 | 0.010 |
Why?
|
Genotype | 1 | 2012 | 12985 | 0.010 |
Why?
|
Cognition Disorders | 1 | 2011 | 3976 | 0.010 |
Why?
|
Brain Mapping | 1 | 2012 | 6635 | 0.010 |
Why?
|
Genomics | 1 | 2012 | 5828 | 0.010 |
Why?
|
Guidelines as Topic | 1 | 2002 | 1385 | 0.010 |
Why?
|
Time Factors | 2 | 2009 | 39957 | 0.010 |
Why?
|
Hospitals | 1 | 2006 | 3881 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 2 | 2011 | 36415 | 0.010 |
Why?
|
Research Design | 1 | 2009 | 6180 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2012 | 12676 | 0.010 |
Why?
|
Longitudinal Studies | 1 | 2009 | 14610 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2012 | 15920 | 0.010 |
Why?
|
Attitude of Health Personnel | 1 | 2003 | 3885 | 0.010 |
Why?
|
Risk Assessment | 1 | 2010 | 24021 | 0.000 |
Why?
|
Prevalence | 1 | 2005 | 15721 | 0.000 |
Why?
|
Reproducibility of Results | 1 | 2005 | 20119 | 0.000 |
Why?
|
Animals | 1 | 2010 | 168079 | 0.000 |
Why?
|